Key Points
- Daniel Allen Gold sold 375,784 shares of Roivant on Feb 13 at an average price of $26.50 for about $9.96M, leaving him with 15,127,329 shares (a 2.42% ownership decline).
- He has executed multiple large insider sales since November — roughly 3.8 million shares sold across Nov–Feb for about $86.7 million in proceeds.
- Despite the insider selling, several analysts raised price targets and institutions added positions, giving a consensus target of ~$28.69 and an average rating of "Moderate Buy" while ROIV trades near its one‑year high (~$26.45).
Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) Director Daniel Allen Gold sold 375,784 shares of the company's stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $26.50, for a total value of $9,958,276.00. Following the sale, the director owned 15,127,329 shares in the company, valued at approximately $400,874,218.50. This represents a 2.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Daniel Allen Gold also recently made the following trade(s):
- On Wednesday, February 11th, Daniel Allen Gold sold 425,000 shares of Roivant Sciences stock. The shares were sold at an average price of $26.67, for a total transaction of $11,334,750.00.
- On Wednesday, December 17th, Daniel Allen Gold sold 777,332 shares of Roivant Sciences stock. The shares were sold at an average price of $23.07, for a total transaction of $17,933,049.24.
- On Tuesday, December 16th, Daniel Allen Gold sold 917,282 shares of Roivant Sciences stock. The stock was sold at an average price of $23.04, for a total transaction of $21,134,177.28.
- On Wednesday, November 19th, Daniel Allen Gold sold 1,300,000 shares of Roivant Sciences stock. The shares were sold at an average price of $20.23, for a total transaction of $26,299,000.00.
Roivant Sciences Price Performance
ROIV opened at $26.45 on Friday. The firm has a market capitalization of $18.40 billion, a P/E ratio of -22.61 and a beta of 1.22. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $27.94. The company has a fifty day moving average price of $22.71 and a 200-day moving average price of $18.31.
Key Roivant Sciences News
Here are the key news stories impacting Roivant Sciences this week:
- Positive Sentiment: Multiple analysts raised price targets and maintained bullish ratings (HC Wainwright, Goldman Sachs, Leerink, Citi — consensus PT ~ $28.69), supporting a positive headline narrative for the stock. MarketBeat ROIV coverage
- Positive Sentiment: Institutional flows show new and increased positions (several funds added ROIV, LPL Financial materially increased its stake), which can provide demand support below recent highs. MarketBeat institutional ownership report
- Neutral Sentiment: HC Wainwright slightly improved its FY2026 EPS view (less negative) and kept a Buy rating with a $33 target — this is mixed for stock moves because estimates remain negative even as the price target was raised. HC Wainwright note
- Negative Sentiment: Director Daniel Allen Gold sold two large blocks (425,000 shares on Feb 11 and 375,784 shares on Feb 13) at ~ $26.50 per share (SEC filing). Large director sales can create near‑term selling pressure and raise investor caution. SEC filing — Daniel Gold sales
- Negative Sentiment: Insider Mayukh Sukhatme sold 339,441 shares on Feb 9 at ~$26.47; this is another sizable insider disposition following previous large sales, which may weigh on sentiment. InsiderTrades / sale report
- Negative Sentiment: HC Wainwright cut several 2027 quarterly EPS forecasts and lowered FY2027 EPS materially (from about -$1.22 to -$1.79), signaling expectations for weaker near‑term financial performance — a clear negative for sentiment until operational catalysts emerge. HC Wainwright estimate update
Institutional Trading of Roivant Sciences
Hedge funds and other institutional investors have recently bought and sold shares of the company. Oregon Public Employees Retirement Fund raised its stake in shares of Roivant Sciences by 0.6% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company's stock worth $1,891,000 after acquiring an additional 500 shares in the last quarter. Bank of Montreal Can grew its holdings in shares of Roivant Sciences by 1.3% during the 4th quarter. Bank of Montreal Can now owns 40,012 shares of the company's stock valued at $868,000 after purchasing an additional 516 shares during the last quarter. Bessemer Group Inc. grew its holdings in shares of Roivant Sciences by 41.5% during the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company's stock valued at $28,000 after purchasing an additional 543 shares during the last quarter. Allworth Financial LP raised its position in Roivant Sciences by 48.1% in the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company's stock worth $27,000 after purchasing an additional 583 shares during the period. Finally, Fifth Third Bancorp lifted its stake in Roivant Sciences by 15.8% in the fourth quarter. Fifth Third Bancorp now owns 4,310 shares of the company's stock worth $94,000 after purchasing an additional 588 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on the company. Wall Street Zen upgraded Roivant Sciences from a "strong sell" rating to a "hold" rating in a research note on Sunday, November 16th. HC Wainwright boosted their price objective on Roivant Sciences from $26.00 to $33.00 and gave the stock a "buy" rating in a report on Tuesday. Jefferies Financial Group reaffirmed a "buy" rating and issued a $30.00 target price on shares of Roivant Sciences in a research note on Monday. The Goldman Sachs Group increased their price target on shares of Roivant Sciences from $24.00 to $33.00 and gave the stock a "buy" rating in a report on Monday, December 15th. Finally, Citigroup raised their price objective on shares of Roivant Sciences from $26.00 to $35.00 and gave the company a "buy" rating in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $28.69.
Read Our Latest Stock Analysis on Roivant Sciences
About Roivant Sciences
(
Get Free Report)
Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.
The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
